You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:
Progen Pharmaceuticals Limited (PGL) is a Brisbane-based biotechnology company specialising in the research and development of potential biopharmaceutical therapeutics for treating cancer (PI-88) and primary liver cancer (PI-166), a devastating disease with few treatment options available to patients.
Company History
Progen was established in 1990, originally focused on the manufacture and supply of molecular biology reagents and kits. Since then, Progen has diversified into the research and development of biopharmaceuticals and contract manufacture. Since its listing in December 1995 at $0.30 per share, the company has focused its activities on its lead compound, an anti-cancer drug called PI-88. PGL was renamed to its current name in April 2007.
Differentiating Factor
PGL specialises in understanding the role of heparan sulfate, a complex sugar, in cancer disease processes and have developed a small-molecule drug development program in this area. PI-88 is currently in Phase II clinical trials for malanoma, liver and lung cancer while PI-166 is in Phase Ib clinical trials.
Major Customers & Competitors
As a biotechnology R&D company, PGL has no customers as such. Nor does it have competition in the true sense of the word, for although there are many biotech firms researching a therapy for cancer, there are many varieties of cancer, and the sufferers have many different needs.
Financial Summary
Year to n/a
NPAT Rep $M
NPAT1 Adj $M
EPS c
EPS chg %
PER x
PER rel All Ords x
PER rel Sector x
DPS c
Yield %
Franking %
ROE %
2004
n/a
0.0
n/a
n/a
0.0
2005
n/a
0.0
n/a
n/a
0.0
2006
n/a
0.0
n/a
n/a
0.0
2007
n/a
0.0
n/a
n/a
0.0
2008
n/a
0.0
n/a
n/a
0.0
2009
n/a
0.0
0.0
0.0
0.0
1NPAT is normalised by removing non-recurring items and goodwill. All the above statistics are derived from normalised earnings.
Sydney Morning Herald 31/07/2010 | GRAINCORP and AWB have agreed on a multibillion-dollar merger so they can compete against larger rivals in the consolidating global agribusiness sector.
The Age 31/07/2010 | GRAINCORP and AWB have agreed to a multibillion-dollar merger in a bid to compete against larger rivals in an increasingly consolidating global agribusiness sector.
Sydney Morning Herald 31/07/2010 | I t's official: money doesn't buy you happiness. But financial security certainly seems to play a role in whether you're a glass half full or glass half empty type of person.
The Age 31/07/2010 | This reporting season will provide something for everyone, from wary retail investors and professional fund managers to stockbroking analysts, writes Ian McIlwraith.
Sydney Morning Herald 31/07/2010 | Most of us want to make a buck and retire early. But for the golden oldies of business, there's no question of quitting, writes Michael Evans.
$ 0.380
